Special Drug Use-Results Survey of Parsabiv

Special Drug Use-Results Survey of Parsabiv [hemodialysis-related secondary hyperparathyroidism]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224015

Enrollment

1200

Registered

2018-07-26

Start date

2018-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism on hemodidalysis

Interventions

investigational material(s) Generic name etc : Parsabiv Intravenous Injection for dialysis 2.5 mg, Parsabiv Intravenous Injection for dialysis 5 mg, Parsabiv Intravenous Injection for dialysis 10 mg I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with secondary hyperparathyroidism on hemodialysis for whom Parsabiv is newly administered

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety items : Occurrence of adverse drug reactions/infections, factors considered to influence the safety Efficacy items : Comprehensive improvement, laboratory test values, factors considered to influence the efficacy	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026